Autoimmune disease therapy - Novartis
Alternative Names: NVS antibodies - NovartisLatest Information Update: 30 Sep 2009
At a glance
- Originator Medarex
- Developer Novartis
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 30 Sep 2009 Discontinued - Phase-I for Autoimmune disorders in Germany (unspecified route)
- 26 Apr 2006 This compound is still in active development
- 17 Jan 2003 Phase-I clinical trials in Autoimmune disorders in Germany (unspecified route)